VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) for the dermatologist
Journal of the American Academy of Dermatology · 2023-12 · 89 (6) · 1209-1214
DOI: 10.1016/j.jaad.2022.01.042 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of the American Academy of Dermatology, 2023-12. Verfasst von David Sterling und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, King's College Hospital, London, United Kingdom. Electronic address: david.sterling3@nhs.net. Hauptthemen laut MEDLINE: Vacuoles, Dermatitis. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
In 2020, Beck et al1 described a novel adult autoinflammatory syndrome entitled VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic), a newly-discovered disorder that connected previously unrelated inflammatory syndromes and a prototype for a new class of hematoinflammatory diseases.2 Eighty-nine percent of published cases have documented skin involvement, but despite the high incidence and diagnostic accessibility of skin manifestations, there has been little focus on the dermatological features of VEXAS syndrome thus far. A PubMed search of all published case reports of VEXAS syndrome to date was performed, with inclusion of all cases confirmed by genetic sequencing, and this review summarizes the reported dermatological signs. There have already been 141 confirmed published cases since original publication, 126 of which had documented cutaneous signs.1-34 A wide range of skin presentations are reported, including Sweet-like urticated and tender erythematous nodules, cartilaginous involvement with chondritis, cutaneous vasculitis, and periorbital angiodema.1-34 Many patients had been diagnosed with Sweet syndrome, relapsing polychondritis, polyarteritis nodosa, or erythema nodosum.1-34 Hallmarks of skin histopathology are a neutrophilic dermatosis with coexisting or exclusive leukocytoclastic vasculitis.1 The new classification therefore helps link previously disparate inflammatory skin conditions into a unifying pathophysiological pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, King's College Hospital, London, United Kingdom. Electronic address: david.sterling3@nhs.net.
- Department of Dermatology, King's College Hospital, London, United Kingdom.
- Department of Histopathology, King's College Hospital, London, United Kingdom.
- Department of Haematology, King's College Hospital, London, United Kingdom.
- Department of Dermatology, King's College Hospital, London, United Kingdom. Electronic address: tanyabasu@nhs.net.
Zitieren
APA
Sterling, D., Duncan, M. E., Philippidou, M., Salisbury, J. R., Kulasekararaj, A. G., & Basu, T. N. (2023). VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) for the dermatologist. Journal of the American Academy of Dermatology, 89(6), 1209-1214. https://doi.org/10.1016/j.jaad.2022.01.042
Vancouver
Sterling D, Duncan ME, Philippidou M, Salisbury JR, Kulasekararaj AG, Basu TN. VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) for the dermatologist. Journal of the American Academy of Dermatology. 2023;89(6):1209-1214. doi:10.1016/j.jaad.2022.01.042
BibTeX
@article{Sterling2023,
author = {Sterling, David and Duncan, Mhairi E and Philippidou, Marianna and Salisbury, Jonathan R and Kulasekararaj, Austin G and Basu, Tanya N},
title = {VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) for the dermatologist},
journal = {Journal of the American Academy of Dermatology},
year = {2023},
volume = {89},
number = {6},
pages = {1209--1214},
doi = {10.1016/j.jaad.2022.01.042}
}
EUVIMED